VERU INC. 10-Q Summary: Quarter Ended December 31, 2025
Business Context and Reporting Period
This report covers the quarterly period ended December 31, 2025. Veru Inc. is a late clinical-stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases. The company has no commercial revenue from continuing operations, having sold its FC2 Female Condom business in December 2024 (classified as discontinued operations) and its ENTADFI assets in 2023. Current development focuses on enobosarm (for obesity/muscle preservation) and sabizabulin (for cardiovascular inflammation).
Key Financial Metrics
| Metric | Q1 2026 (Ended Dec 31, 2025) | Q1 2025 (Ended Dec 31, 2024) |
|---|---|---|
| Revenue | $0 | $0 (Continuing Ops) |
| Net Loss | $(5.33) million | $(8.95) million |
| Operating Expenses | $5.42 million | $10.94 million |
| Cash & Equivalents | $33.0 million | $26.6 million |
| Working Capital | $29.7 million | N/A (Prior period included discontinued ops) |
| Stockholders' Equity | $37.1 million | $26.6 million |
Cash Flow: Net cash used in operating activities was $6.2 million. Net cash provided by financing activities was $23.4 million, driven by a public offering. There were no investing cash flows in the current quarter.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately 50% to $5.42 million from $10.94 million. Research and Development (R&D) expenses dropped to $1.34 million from $5.72 million due to the wind-down of the Phase 2b QUALITY clinical study. General and Administrative (G&A) expenses fell to $4.08 million from $5.23 million, largely due to reduced share-based compensation.
- Financing Activity: In October 2025, the company completed an underwritten public offering raising approximately $23.4 million in net proceeds. This included the sale of common stock, pre-funded warrants, and Series A/B warrants.
- Debt Extinguishment: The prior period included an $8.6 million gain on extinguishment of debt related to the FC2 business sale, which did not recur in the current period.
- Settlement of Receivables: The company settled outstanding promissory notes from the ENTADFI asset sale with Onconetix, Inc. (ONCO) for $6.3 million cash plus equity securities (Series D Preferred Stock and warrants), resolving $8.8 million in receivables.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for twelve months following the issuance date. Current cash is insufficient to fund operations without additional financing.
- Clinical Outlook:
- Enobosarm: Following positive Phase 2b results showing muscle preservation and fat loss, the company plans a Phase 2b PLATEAU study starting in Q1 2026. The FDA has indicated that incremental weight loss is an acceptable primary endpoint.
- Sabizabulin: The company is exploring development for atherosclerotic cardiovascular disease, planning a small Phase 2 dose-finding study to assess inflammation reduction.
- Risks: Key risks include the need for substantial capital, potential delays in clinical trials, regulatory approval uncertainties, and ongoing shareholder litigation regarding prior disclosures. The company also faces risks related to the valuation of its ONCO equity securities.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion given the "substantial doubt" going concern disclosure and the burn rate of ~$6.2 million per quarter.
- Financing Terms: Review the dilution impact of the 7 million pre-funded warrants and 16.8 million Series A/B warrants issued in the October 2025 offering.
- ONCO Settlement: Assess the fair value and liquidity of the ONCO Series D Preferred Stock and warrants received in lieu of full cash payment for the ENTADFI notes.
- Legal Exposure: Monitor the status of the "Shareholder Litigation" (Ewing, Maglia, Franchi, etc.) and the "Clear Future Lawsuit" regarding the FC2 sale, as potential losses are currently unquantifiable.
- Phase 2b PLATEAU: Confirm the initiation date and funding allocation for the upcoming PLATEAU study, which is critical for the enobosarm program.